atrial fibrillation
Conditions
Interventions
Control Group:Xinsuning Capsules Placebo + interventionropafenone Hvdrochloride
Treatment Group:Xinsuning Capsules +roceyentionPropafenone HydrochloridePlacebo
Sponsors
Shandong University of Traditional Chinese Medicine Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: RCT: (1) Meets the Western diagnostic criteria for paroxysmal atrial fibrillation; (2) Meets the traditional Chinese medicine differentiation criteria for phlegm heat disturbing the heart syndrome; (3) The frequency of atrial fibrillation attacks is 22 times per month; (4) Age between 18 and 80 years old gender not limited; (5) The patient provides informed consent and signs the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Merge severe cardiovascular diseases including hypertension grade 3 or above valvular heart disease congenital heart disease acute coronary syndrome requiring revascularization etc; (2) Heart failure with NYHA grade IV or reduced ejection fraction; (3) Patients with poorly controlled hyperthyroidism sleep apnea syndrome diabetes (glycosylated hemoglobin value exceeds 10%) acute exacerbation of chronic obstructive pulmonary disease severe autoimmune disease and malignant tumor; (4) Obese patients (BMI = 28kg/m2); (5) Patients with severe primary diseases of the brain liver kidney and hematopoietic systems as well as psychiatric disorders who have alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels greater than twice the upper limit of normal values and blood creatinine (Scr) levels greater than the upper limit of normal values; (6) Life expectancy<1 year; (7) Individuals with allergic constitution and those who are allergic to drug ingredients in known experimental drugs; (8) Women or partners who are pregnant breastfeeding or have plans to conceive in the near future; (9) Participate in other clinical studies within one month prior to screening; (10) Researchers believe that individuals who are not suitable to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| oosaden of atrial fibrllation;chesode,er of atrial fibrilation;Atrial Fibrillation Burden; | — |
Secondary
| Measure | Time frame |
|---|---|
| Additional indicators for blood routine and urine routine: Kidney function;Second Use RateReuse Rate;Heart rate heart rate variability maximum P-wave index secondary index type time limit and P-wave dispersion changes;Cicas haee cfie sinoranes; | — |
Countries
China
Contacts
Public ContactYifei Wang
The Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Outcome results
None listed